# US 8,784,900 B2 · Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,784,900 B2 - Document ID: US8784900B2 - Status: Granted - Kind: B2 - Application number: 12/531,276 - Filed: 2008-03-13 - Published: 2010-05-06 - Granted: 2014-07-22 - Earliest claimed: 2007-03-13 - Assignees: Oculus Innovative Sciences, Inc. - Applicants: Robert Northey - Inventors: Robert Northey - Web page: https://patentgrep.com/patent/US8784900B2 ## CPC - A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine - A61K 33/00: Medicinal preparations containing inorganic active ingredients - A61K 47/02: Inorganic compounds - A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids - A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis - A61P 11/00: Drugs for disorders of the respiratory system - A61P 11/02: Nasal agents, e.g. decongestants - A61P 17/00: Drugs for dermatological disorders - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 27/02: Ophthalmic agents - A61P 27/16: Otologicals - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 31/10: Antimycotics - A61P 31/12: Antivirals - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial. ## Claims ### Claim 1 An antimicrobial solution, comprising: a first component comprising an effective amount of a hypochlorous acid solution, wherein the hypochlorous acid solution has a pH of about 4 to about 6, and wherein the hypochlorous acid solution comprises a buffer selected from the group consisting of a phosphate buffer, acetate buffer, citrate buffer, borate buffer, and combinations thereof; and a second component comprising a catalyst, which catalyzes the conversion of hypochlorous acid into dichlorine monoxide, wherein, when the first and second components are combined, the combination produces an activated solution comprising a therapeutically effective amount of dichlorine monoxide, and wherein the activated solution has a pH in a range of from about 4 to about 10. ### Claim 2 (depends on 1) The solution of claim 1, wherein the hypochlorous acid solution has a pH of from about 5.0 to about 6.0. ### Claim 3 (depends on 1) The solution of claim 1, wherein the catalyst is selected from the group consisting of a phosphate ion, chloride ion, tertiary amine, sodium hypochlorite, citric acid, and combinations thereof. ### Claim 4 (depends on 1) The solution of claim 1, wherein the catalyst is triethanolamine. ### Claim 5 (depends on 4) The solution of claim 4, wherein the triethanolamine is present in a concentration of about 0.3 ppm to about 1.5 ppm. ### Claim 6 (depends on 1) The solution of claim 1, wherein the activated solution has a pH of from about 5.0 to about 6.0. ### Claim 7 (depends on 1) The solution of claim 1, wherein the hypochlorous acid solution is contained within a first container, and the catalyst is contained within a second container. ### Claim 8 A method for treating a wound or infection in a mammal, the method comprising: adding to a solution comprising an effective amount of hypochlorous acid a catalyst, which catalyzes the conversion of hypochlorous acid into dichlorine monoxide, to produce an activated solution comprising a therapeutically effective amount of dichlorine monoxide; and administering the activated solution to treat the wound or infection, wherein the hypochlorous acid solution has a pH of about 4 to about 6, wherein the activated solution has a pH in a range of from about 4 to about 10, and wherein the hypochlorous acid solution further comprises a buffer selected from the group consisting of a phosphate buffer, acetate buffer, citrate buffer, borate buffer, and combinations thereof. ### Claim 9 (depends on 8) The method of claim 8, wherein the hypochlorous acid solution has a pH of from about 5.0 to about 6.0. ### Claim 10 (depends on 8) The method of claim 8, wherein the catalyst is selected from the group consisting of a phosphate ion, chloride ion, tertiary amine, sodium hypochlorite, citric acid, and combinations thereof. ### Claim 11 (depends on 8) The method of claim 8, wherein the catalyst is triethanolamine present in a concentration of about 0.3 ppm to about 1.5 ppm. ### Claim 12 (depends on 8) The method of claim 8, wherein the activated solution has a pH of from about 5.0 to about 6.0. ### Claim 13 (depends on 8) The method of claim 8, wherein the infection is caused by the bacteria Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae, Acinetobacter baumannii, Acinetobacter species, Bacteroides fragilis, Enterobacter aerogenes, Enterococcus faecalis, Vancomycin resistant-Enterococcus faecium (VRE, MDR), Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Micrococcus luteus, Proteus mirabilis, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, Salmonella choleraesuis, Shigella dysenteriae or a combination thereof. ### Claim 14 (depends on 8) The method of claim 8, wherein the wound is an oral ulcer, skin ulcer, burn, peritonitis, periodontal disease, gingival disease or a combination thereof. ### Claim 15 (depends on 14) The method of claim 14, wherein the skin ulcer is a diabetic foot ulcer. ### Claim 16 (depends on 8) The method of claim 8, wherein the infection is a pulmonary, ophthalmic, otic, nasal or sinus infection. ### Claim 17 (depends on 16) The method of claim 16, wherein the pulmonary infection is in a human mammal afflicted with cystic fibrosis. ### Claim 18 A method for disinfecting a surface, the method comprising: adding to a solution comprising an effective amount of hypochlorous acid a catalyst, which catalyzes the conversion of hypochlorous acid into dichlorine monoxide, to produce an activated solution comprising a surface-disinfecting effective amount of dichlorine monoxide; and contacting the surface with the activated solution to disinfect the surface, wherein the hypochlorous acid solution has a pH of about 4 to about 6, wherein the activated solution has a pH in a range of from about 4 to about 10, and wherein the hypochlorous acid solution further comprises a buffer selected from the group consisting of a phosphate buffer, acetate buffer, citrate buffer, borate buffer, and combinations thereof. ### Claim 19 (depends on 18) The method of claim 18, wherein the hypochlorous acid solution has a pH of from about 5.0 to about 6.0. ### Claim 20 (depends on 18) The method of claim 18, wherein the catalyst is selected from the group consisting of a phosphate ion, chloride ion, tertiary amine, sodium hypochlorite, citric acid, and combinations thereof. ### Claim 21 (depends on 18) The method of claim 18, wherein the catalyst is triethanolamine in a concentration of about 0.3 ppm to about 1.5 ppm. ### Claim 22 (depends on 18) The method of claim 18, wherein the surface is a plastic surface, metal surface, glass surface or a combination thereof. ### Claim 23 (depends on 18) The method of claim 18, wherein the surface is on an artificial heart valve, orthopedic appliance, implantable pacemaker, implantable tube, implantable stent, implantable mesh or a combination thereof. ### Claim 24 (depends on 23) The method of claim 23, wherein the surface is on a bronchoscope, colonoscope, sigmoidoscope, hysteroscope, laproscope, arthroscope, gastroscope or cystoscope. ### Claim 25 (depends on 1) The solution of claim 1, wherein the hypochlorous acid solution is prepared by electrolysis. ### Claim 26 (depends on 1) The solution of claim 1, wherein the hypochlorous acid solution is prepared by dissolving chlorine in a dilute aqueous alkali metal hydroxide solution. ### Claim 27 (depends on 8) The solution of claim 8, wherein the hypochlorous acid solution is prepared by electrolysis. ### Claim 28 (depends on 8) The solution of claim 8, wherein the hypochlorous acid solution is prepared by dissolving chlorine in a dilute aqueous alkali metal hydroxide solution. ### Claim 29 (depends on 18) The solution of claim 18, wherein the hypochlorous acid solution is prepared by electrolysis. ### Claim 30 (depends on 18) The solution of claim 18, wherein the hypochlorous acid solution is prepared by dissolving chlorine in a dilute aqueous alkali metal hydroxide solution.